ASO Author Reflections: Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma

Mahuron, Kelly; Levine, Lauren P.; Daud, Adil

doi:10.1245/s10434-020-08672-7

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As suggested in the OpACIN-neo trial, pathologic response is an important marker for RFS, even if its long-term benefits remain to be proven [ 52 ]. In a small prospective study, 20% of patients treated with neoadjuvant immunotherapy (both a mono- and combination-regimen) avoided surgical management due to a complete radiological response and remained recurrence-free at a median follow up of 31.8 months [ 54 ]. This opens up the possibility for the more conservative management of patients to achieve pCR.…”

Section: Neoadjuvant Immunotherapymentioning

confidence: 99%

“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers

Garutti

Buriolla

Bertoli

et al. 2020

Cancers

View full text Add to dashboard Cite

Despite surgical resection and adjuvant therapies, stage III melanomas still have a substantial risk of relapse. Neoadjuvant therapy is an emerging strategy that might offer superior efficacy compared to adjuvant therapy. Moreover, neoadjuvant therapy has some virtual advantages: it might allow for less demolitive surgery, permit the in vivo evaluation of drug efficacy, help tailor adjuvant treatments, and play a crucial role in innovative translational research. Herein, we review the available literature to explore the scientific background behind the neoadjuvant approach. We also discuss published clinical trials with a focus on predictive biomarkers and ongoing studies. Finally, we outline a possible framework for future neoadjuvant clinical trial development based on the International Neoadjuvant Melanoma Consortium guidelines.

show abstract

Section: Neoadjuvant Immunotherapymentioning

confidence: 99%